Skip to main content
. Author manuscript; available in PMC: 2023 Nov 1.
Published in final edited form as: Transplant Cell Ther. 2022 Jul 22;28(11):727–736. doi: 10.1016/j.jtct.2022.07.015

Figure 1. Current state of hematologic malignancy indications for CAR T, AlloHCT, and AutoHCT.

Figure 1.

These diseases reflect potential indications for the three cellular therapy platforms. Importantly, however, these platforms are generally not interchangeable and the selection of the appropriate modality must be tailored to the disease biology and treatment history of each individual patient. MM, multiple myeloma; PCNSL, primary CNS lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; DLBCL, diffuse large B-cell lymphoma; B-ALL, B-cell acute lymphoblastic leukemia; cHL, classical Hodgkin lymphoma; PTCL, peripheral T-cell lymphoma; T-ALL, T-cell acute lymphoblastic leukemia; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; MF, myelofibrosis; MPN, myeloproliferative neoplasm